

Registration No. 333-272006  
Registration No. 333-270185  
Registration No. 333-266334  
Registration No. 333-262995  
Registration No. 333-260917  
Registration No. 333-253896  
Registration No. 333-238065  
Registration No. 333-236720  
Registration No. 333-234404  
Registration No. 333-229982  
Registration No. 333-223537  
Registration No. 333-219656  
Registration No. 333-211916  
Registration No. 333-208893  
Registration No. 333-202438  
Registration No. 333-193694  
Registration No. 333-191767

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**POST-EFFECTIVE AMENDMENT NO. 1  
TO  
FORM S-8 REGISTRATION STATEMENT NO. 333-272006  
FORM S-8 REGISTRATION STATEMENT NO. 333-270185  
FORM S-8 REGISTRATION STATEMENT NO. 333-266334  
FORM S-8 REGISTRATION STATEMENT NO. 333-262995  
FORM S-8 REGISTRATION STATEMENT NO. 333-260917  
FORM S-8 REGISTRATION STATEMENT NO. 333-253896  
FORM S-8 REGISTRATION STATEMENT NO. 333-238065  
FORM S-8 REGISTRATION STATEMENT NO. 333-236720  
FORM S-8 REGISTRATION STATEMENT NO. 333-234404  
FORM S-8 REGISTRATION STATEMENT NO. 333-229982  
FORM S-8 REGISTRATION STATEMENT NO. 333-223537  
FORM S-8 REGISTRATION STATEMENT NO. 333-219656  
FORM S-8 REGISTRATION STATEMENT NO. 333-211916  
FORM S-8 REGISTRATION STATEMENT NO. 333-208893  
FORM S-8 REGISTRATION STATEMENT NO. 333-202438  
FORM S-8 REGISTRATION STATEMENT NO. 333-193694  
FORM S-8 REGISTRATION STATEMENT NO. 333-191767  
UNDER  
THE SECURITIES ACT OF 1933**

---

**IVERIC bio, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**8 Sylvan Way**  
**Parsippany, NJ**  
(Address of Principal Executive Offices)

**20-8185347**  
(I.R.S. Employer  
Identification Number)

**07054**  
(Zip Code)

**2023 Stock Incentive Plan  
2019 Inducement Stock Incentive Plan, as amended  
2013 Stock Incentive Plan, as amended  
2016 Employee Stock Purchase Plan  
Inducement Stock Option Grants  
Amended and Restated 2007 Stock Incentive Plan, as amended**

(Full title of the plans)

Catherine Levitt  
General Counsel  
Astellas Pharma US, Inc.  
2375 Waterview Drive  
Northbrook, IL 60062-6111  
(800) 727-7003

(Name, address, and telephone number, including area code, of agent for service)

---

Copy to:  
Jon Beeson  
Ben Chouka  
Jones Day  
3161 Michelson Drive, Suite 800  
Irvine, CA 92612  
(949) 851-3939

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

## DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (the “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (the “Registration Statements”) filed by IVERIC bio, Inc. (“IVERIC” or the “Company”) with the Securities and Exchange Commission (the “SEC”):

- [Registration Statement No. 333-272006, filed with the SEC on May 17, 2023](#), relating to the registration of 19,259,019 shares of common stock, \$0.001 par value per share (“Shares”) of the Company under the Company’s 2023 Stock Incentive Plan;
  - [Registration Statement No. 333-270185, filed with the SEC on March 1, 2023](#), relating to the registration of (i) 2,542,372 Shares under the Company’s 2013 Stock Incentive Plan, as amended and (ii) 2,000,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-266334, filed with the SEC on July 26, 2022](#), relating to the registration of 1,000,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-262995, filed with the SEC on February 24, 2022](#), relating to the registration of (i) 2,542,372 Shares under the Company’s 2013 Stock Incentive Plan, as amended and (ii) 1,000,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-260917, filed with the SEC on November 9, 2021](#), relating to the registration of 1,000,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-253896, filed with the SEC on March 5, 2021](#), relating to the registration of (i) 2,542,372 Shares under the Company’s 2013 Stock Incentive Plan, as amended and (ii) 600,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-238065, filed with the SEC on May 7, 2020](#), relating to the registration of 1,000,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-236720, filed with the SEC on February 27, 2020](#), relating to the registration of 1,985,082 Shares under the Company’s 2013 Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-234404, filed with the SEC on October 31, 2019](#), relating to the registration of 1,000,000 Shares under the Company’s 2019 Inducement Stock Incentive Plan;
  - [Registration Statement No. 333-229982, filed with the SEC on March 1, 2019](#), relating to the registration of 1,655,887 Shares under the Company’s 2013 Stock Incentive Plan, as amended;
  - [Registration Statement No. 333-223537, filed with the SEC on March 9, 2018](#), relating to the registration of 1,444,411 Shares under the Company’s 2013 Stock Incentive Plan;
  - [Registration Statement No. 333-219656, filed with the SEC on August 3, 2017](#), relating to the registration of 1,429,394 Shares under the Company’s 2013 Stock Incentive Plan;
  - [Registration Statement No. 333-211916, filed with the SEC on June 8, 2016](#), relating to the registration of 1,000,000 Shares under the Company’s 2016 Employee Stock Purchase Plan;
  - [Registration Statement No. 333-208893, filed with the SEC on January 6, 2016](#), relating to the registration of (i) 1,407,799 Shares under the Company’s 2013 Stock Incentive Plan and (ii) 120,000 Shares under an inducement stock option grant;
  - [Registration Statement No. 333-202438, filed with the SEC on March 2, 2015](#), relating to the registration of (i) 1,359,781 Shares under the Company’s 2013 Stock Incentive Plan and (ii) 350,000 Shares under an inducement stock option grant;
  - [Registration Statement No. 333-193694, filed with the SEC on January 31, 2014](#), relating to the registration of 1,256,528 Shares under the Company’s 2013 Stock Incentive Plan; and
  - [Registration Statement No. 333-191767, filed with the SEC on October 16, 2013](#), relating to the registration of (i) 739,317 Shares under the Company’s 2013 Stock Incentive Plan and (ii) 2,620,324 Shares under the Company’s Amended and Restated 2007 Stock Incentive Plan, as amended.
-

On July 11, 2023, Berry Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Astellas US Holding, Inc., a Delaware corporation (“Parent”), completed its merger (the “Merger”) with and into IVERIC pursuant to the terms of the Agreement and Plan of Merger, dated April 28, 2023 (the “Merger Agreement”), by and among Parent, Merger Sub, IVERIC, and solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc., a company organized under the laws of Japan. IVERIC was the surviving corporation in the Merger and, as a result, is now a wholly owned subsidiary of Parent.

As a result of the Merger, IVERIC has terminated all offerings and sales of securities pursuant to the Registration Statements. In accordance with an undertaking made by IVERIC in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance under the Registration Statements that remain unsold at the termination of such offerings, IVERIC hereby removes from registration all of such securities registered but remaining unsold under the Registration Statements as of the date hereof.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements described above to be signed on its behalf by the undersigned, thereunto duly authorized, in Parsippany, New Jersey, on July 11, 2023.

**IVERIC bio, Inc.**

By: /s/ Mark Reisenauer

Name: Mark Reisenauer

Title: President, Secretary and Treasurer

No other person is required to sign these Post-Effective Amendments in reliance on Rule 478 of the Securities Act of 1933.

---